Usefulness of precision medicine in improving prevention, treatment and prognosis in oncology
Utilidad en la prevención, tratamiento y pronóstico de la medicina de precisión en oncología
Main Article Content
Abstract
Introduction: advances in genetics in recent decades has ushered a new era. Precision medicine has used these advances to play an increasingly important role in cancer prevention, diagnosis and treatment. Objetive: was to evaluate the usefulness of precisión medicine in improving prevention, treatment and prognosis in oncology. Discussion: studies on carcinogenesis have propelled the discovery of crucial events in the development of malignant neoplasms, identifying specific molecular subtypes of several common tumors. This has resulted in a better charaterization of tumors, which previously depended only on anatomapathological findings, and has enabled the development of new drugs, which have shifted the oncologic care paradigm. The identification of mutations that may determine predisposition to cancer, such as, BRCA mutations in breast cáncer, has facilitated screening to identify patients and help improve decision making and modify risk. Conclusions: the efficacy of various antitumor therapies suggests the beginning of an era in which preventive actions and clinical decisions will be based on the profile of genetic abnormalities of the tumor, improving patient prognosis and quality of life. This will allow an increase in the use of this type of precision treatments based on the profile of genetic changes.
Keywords:
Downloads
Article Details
References
Santos-Cortez RLP, Bhutta MF, Earl JP, Hafrén L, Jennings M, Mell JC, Pichichero ME, Ryan AF, Tateossian H, Ehrlich GD. Panel 3: Genomics, precision medicine and targeted therapies. Int J Pediatr Otorhinolaryngol. 2020;130 Suppl 1(Suppl 1):109835. doi: 10.1016/j.ijporl.2019.109835. DOI: https://doi.org/10.1016/j.ijporl.2019.109835
Amekyeh H, Tarlochan F, Billa N. Practicality of 3D printed personalized medicines in therapeutics. Front Pharmacol. 2021;12:646836. doi: 10.3389/fphar.2021.646836. DOI: https://doi.org/10.3389/fphar.2021.646836
Hebar A, Valent P, Selzer E. The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Rev Clin Pharmacol. 2013;6(1):23-34. doi: 10.1586/ecp.12.71. DOI: https://doi.org/10.1586/ecp.12.71
Yu Z, Song M, Chouchane L, Ma X. Functional genomic analysis of breast cancer metastasis: implications for diagnosis and therapy. Cancers (Basel). 2021;13(13):3276. doi: 10.3390/cancers13133276. DOI: https://doi.org/10.3390/cancers13133276
Huebner T, Scholl C, Steffens M. Cytogenetic and biochemical genetic techniques for personalized drug therapy in Europe. Diagnostics (Basel). 2021;11(7):1169. doi: 10.3390/diagnostics11071169. DOI: https://doi.org/10.3390/diagnostics11071169
Norrie JL, Nityanandam A, Lai K, Chen X, Wilson M, Stewart E, Griffiths L, Jin H, Wu G, Orr B, Tran Q, Allen S, Reilly C, Zhou X, Zhang J, Newman K, Johnson D, Brennan R, Dyer MA. Retinoblastoma from human stem cell-derived retinal organoids. Nat Commun. 2021;12(1):4535. doi: 10.1038/s41467-021-24781-7. DOI: https://doi.org/10.1038/s41467-021-24781-7
Heck JE, Huang X, Calkins KL, Sun Y, Olsen J, Ritz B, Hansen J. Phototherapy and childhood cancer: Shared risk factors. Int J Cancer. 2020;146(7):2059-2062. doi: 10.1002/ijc.32701. DOI: https://doi.org/10.1002/ijc.32701
Houlston R. Identification of low-penetrance alleles associated with colon cancer risk. Med Sci (Paris). 2009;25 Spec No 1:39-41. doi: 10.1051/medsci/2009251s39. DOI: https://doi.org/10.1051/medsci/2009251s39
Capellini A, Williams M, Onel K, Huang KL. The functional hallmarks of cancer predisposition genes. Cancer Manag Res. 2021;13:4351-4357. doi: 10.2147/CMAR.S311548. DOI: https://doi.org/10.2147/CMAR.S311548
Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP. Genetic testing and screening recommendations for patients with hereditary breast cancer. Radiographics. 2020;40(4):913-936. doi: 10.1148/rg.2020190181. DOI: https://doi.org/10.1148/rg.2020190181
Howard TP, Vazquez F, Tsherniak A, Hong AL, Rinne M, Aguirre AJ, Boehm JS, Hahn WC. Functional genomic characterization of cancer genomes. Cold Spring Harb Symp Quant Biol. 2016;81:237-246. doi: 10.1101/sqb.2016.81.031070. DOI: https://doi.org/10.1101/sqb.2016.81.031070
Kutkowska J, Strzadala L, Rapak A. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. Cancer Sci. 2017;108(11):2265-2272. doi: 10.1111/cas.13386. DOI: https://doi.org/10.1111/cas.13386
Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5(1):90. doi: 10.1038/s41392-020-0196-9. DOI: https://doi.org/10.1038/s41392-020-0196-9
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. DOI: https://doi.org/10.1016/j.cell.2011.02.013
Gisselsson D, Egnell R. Cancer - An insurgency of clones. Trends Cancer. 2017;3(2):73-75. doi: 10.1016/j.trecan.2016.11.010. DOI: https://doi.org/10.1016/j.trecan.2016.11.010
Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol. 2011;32(3):425-40. doi: 10.1007/s13277-011-0155-8. DOI: https://doi.org/10.1007/s13277-011-0155-8
Beijnen JH, Schellens JH. Personalized medicine in oncology: a personal view with myths and facts. Curr Clin Pharmacol. 2010;5(3):141-7. doi: 10.2174/157488410791498789. DOI: https://doi.org/10.2174/157488410791498789
Vishwakarma R, McManus KJ. Chromosome instability; Implications in cancer development, progression, and clinical outcomes. Cancers (Basel). 2020;12(4):824. doi: 10.3390/cancers12040824. DOI: https://doi.org/10.3390/cancers12040824
Mainor CB, Isaacs C. Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer. Curr Breast Cancer Rep. 2020;12(2):66-74. doi: 10.1007/s12609-019-00350-2. DOI: https://doi.org/10.1007/s12609-019-00350-2
Lewis KM. Identifying hereditary cancer: genetic counseling and cancer risk assessment. Curr Probl Cancer. 2014;38(6):216-25. doi: 10.1016/j.currproblcancer.2014.10.002. DOI: https://doi.org/10.1016/j.currproblcancer.2014.10.002
McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141(2):210-7. doi: 10.1016/j.cell.2010.03.032. DOI: https://doi.org/10.1016/j.cell.2010.03.032
Tian H, Gao Z, Li H, Zhang B, Wang G, Zhang Q, Pei D, Zheng J. DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358(1):8-16. doi: 10.1016/j.canlet.2014.12.038. DOI: https://doi.org/10.1016/j.canlet.2014.12.038
Szczerba E, Kamińska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA. BRCA1/2 mutation detection in the tumor tissue from selected polish patients with breast cancer using Next Generation Sequencing. Genes (Basel). 2021;12(4):519. doi: 10.3390/genes12040519. DOI: https://doi.org/10.3390/genes12040519
Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, Hoffman D, Jang W, Kaur K, Liu C, Lyoshin V, Maddipatla Z, Maiti R, Mitchell J, O'Leary N, Riley GR, Shi W, Zhou G, Schneider V, Maglott D, Holmes JB, Kattman BL. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835-D844. doi: 10.1093/nar/gkz972. DOI: https://doi.org/10.1093/nar/gkz972
Dumbrava EI, Meric-Bernstam F. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Stud. 2018;4(2):a001578. doi: 10.1101/mcs.a001578. DOI: https://doi.org/10.1101/mcs.a001578
Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, Gallagher S, Meek S, Dalton K, Hedegard W, Adami CA, Grear DF, Domchek SM, Garber J, Lancaster JM, Weitzel JN, Kurian AW, Lanchbury JS, Gutin A, Robson ME. Integrating clinical and polygenic factors to predict breast cancer risk in women undergoing genetic testing. JCO Precis Oncol. 2021;5:PO.20.00246. doi: 10.1200/PO.20.00246. DOI: https://doi.org/10.1200/PO.20.00246
Qiu J, Xu J, Zhang K, Gu W, Nie L, Wang G, Luo Y. Refining cancer management using integrated liquid biopsy. Theranostics. 2020;10(5):2374-2384. doi: 10.7150/thno.40677. DOI: https://doi.org/10.7150/thno.40677
Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system. Ann Oncol. 2019;30(8):1265-1278. doi: 10.1093/annonc/mdz164. DOI: https://doi.org/10.1093/annonc/mdz164
Elkamhawy A, Lu Q, Nada H, Woo J, Quan G, Lee K. The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer. Int J Mol Sci. 2021;22(12):6535. doi: 10.3390/ijms22126535. DOI: https://doi.org/10.3390/ijms22126535
Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3-4):79-100. doi: 10.1142/S2339547818300020. DOI: https://doi.org/10.1142/S2339547818300020
Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized medicine in malignant melanoma: Towards patient tailored treatment. Front Oncol. 2018;8:202. doi: 10.3389/fonc.2018.00202. DOI: https://doi.org/10.3389/fonc.2018.00202
Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol. 2019;53(3):265-274. doi: 10.2478/raon-2019-0033. DOI: https://doi.org/10.2478/raon-2019-0033
von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 2013;8(3):193-202. doi: 10.2174/1574362409666140206221931. DOI: https://doi.org/10.2174/1574362409666140206221931
Vieira AF, Schmitt F. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front Med (Lausanne). 2018;5:248. doi: 10.3389/fmed.2018.00248. DOI: https://doi.org/10.3389/fmed.2018.00248
Schildgen V, Warm M, Brockmann M, Schildgen O. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR. Sci Rep. 2019;9(1):20266. doi: 10.1038/s41598-019-56910-0. DOI: https://doi.org/10.1038/s41598-019-56910-0